Keay Nakae analyst CHARDAN CAPITAL

Currently, out of the existing stock ratings of Keay Nakae - 98 which are a Buy (78.4%), 19 which are a Hold (15.2%), 8 which are a Sell (6.4%)

Keay Nakae

Work Performance Price Targets & Ratings Chart

Analyst Keay Nakae works at CHARDAN CAPITAL and is covering the Healthcare sector with 208 price targets and ratings displayed on 30 stocks.

Keay Nakae's average stock forecast success ratio is 38.21% with an average time for price targets to be met of 63.29 days.

Most recent stock forecast was given on PRQR, ProQR Therapeutics N.V at 08-Nov-2023.

Wall Street Analyst Keay Nakae

Analyst best performing recommendations are on OCGN (OCUGEN).
The best stock recommendation documented was for OCGN (OCUGEN) at 2/8/2021. The price target of $13 was fulfilled within 1 day with a profit of $2.81 (17.77%) receiving and performance score of 177.74.

Average potential price target upside

ABUS Arbutus Biopharma ARWR Arrowhead Pharmaceuticals AXLA Axcella Health DRNA Dicerna Pharmaceuticals EBS Emergent BioSolutions KLDO Kaleido BioSciences MESO Mesoblast OCGN Ocugen PEAR SONN EVLO Evelo Biosciences FBRX LJPC La Jolla Pharmaceutical Company PHGE PRQR ProQR Therapeutics N.V CFRX FEMY NBSE RNA SABS MCRB Seres Therapeutics SYBX Synlogic ALNY Alnylam Pharmaceuticals BTTX DYN GANX KMDA OCX OncoCyte SLN XCUR

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$3.97 (195.57%)


2 months 23 days ago

0/8 (0%)

$3.75 (150.13%)



$3.97 (195.57%)


4 months 29 days ago

0/3 (0%)

$4.35 (169.15%)



$2.97 (146.31%)

1 years 10 months 3 days ago

0/1 (0%)

$2.11 (73.01%)



2 years 5 months 7 days ago

0/2 (0%)

$6.88 (220.99%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Keay Nakae is most bullish on?

Potential upside of $78.59 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Keay Nakae is most reserved on?

Potential downside of -$0 has been obtained for ARWR (ARROWHEAD PHARMACEUTICALS)

What Year was the first public recommendation made by Keay Nakae?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart